Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | $55.00 | Neutral | Cantor Fitzgerald |
| 4/22/2025 | Overweight | Piper Sandler | |
| 12/16/2024 | $70.00 | Hold → Buy | Jefferies |
| 12/10/2024 | $63.00 | Neutral | BofA Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/13/2024 | Neutral → Outperform | Daiwa Securities | |
| 11/12/2024 | $73.00 | Market Perform → Outperform | Leerink Partners |
| 10/25/2024 | $75.00 → $55.00 | Buy → Neutral | Citigroup |
For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. “Schizophrenia is a leading
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and
Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3 in Chicago, Illinois. Data from more than 80 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning more than 20 cancer types. "Bristol Myers Squibb is advancing novel approaches to address high unmet needs in cancer and at this year's ASCO meeting, we are highlighting data across a range of assets, including our targeted therapy pipeline, and new data that support the use of our portfolio in earlier lines of treatment, enhancing o
Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Bernstein 41st Annual Strategic Decisions Conference on Wednesday, May 28, 2025. The company will take part in a fireside chat beginning at 3:30 p.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's pos
Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo Opdivo is now the only PD-(L)1 inhibitor approved for both perioperative and neoadjuvant-only treatment of resectable non-small cell lung cancer in the European Union Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo® (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo for the treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patien
Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq
Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d
8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00
Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight
Jefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)